ANTI-PROGRAMMED DEATH-LIGAND 1 (PD-L1) ANTIBODIES AND THERAPEUTIC USES THEREOF

摘要

Anti-programmed death-ligand 1 (PD-L1) antibodies, methods of using the same, therapeutic compositions thereof, and uses thereof in upregulating cell-mediated immune responses and treating T cell dysfunctional disorders are provided. The use of the anti-PD-L1 antibody as a diagnostic agent in vitro is also provided.